Theseus Pharmaceuticals, Inc.
THRX

$181.5 M
Marketcap
$4.07
Share price
Country
$0.01
Change (1 day)
$12.37
Year High
$2.05
Year Low
Categories

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

marketcap

P/B ratio for Theseus Pharmaceuticals, Inc. (THRX)

P/B ratio as of 2022: 0.92

According to Theseus Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.92. At the end of 2021 the company had a P/B ratio of 0.50.

P/B ratio history for Theseus Pharmaceuticals, Inc. from 2019 to 2022

P/B ratio at the end of each year

Year P/B ratio
2022 0.92
2021 0.50
2020 -13.75
2019 -23.54